Literature DB >> 16612622

Endoglin (CD105) as a prognostic factor in head and neck squamous cell carcinoma.

Panayiotis A Kyzas1, Niki J Agnantis, Dimitrios Stefanou.   

Abstract

Endoglin (CD105) is a proliferation-associated protein abundantly expressed in angiogenic endothelial cells. Recent studies revealed that CD105 is intensively expressed in tumor vasculature, whereas intratumoral microvessel density (MVD) determined with the use of antibodies to CD105 has been found to be an important prognostic indicator for the outcome in a number of malignancies. In the current study, we investigated endoglin expression and evaluated MVD in 108 patients with head and neck squamous cell carcinoma. Endoglin was intensively expressed in intratumoral blood vessels, whilst lymphatics were rarely positive for CD105. High microvessel density was associated with a more aggressive tumor phenotype, including advanced clinical stage (p = 0.008) and the presence of lymph node metastasis at the time of diagnosis (p = 0.02). When microvessel counts were assessed for their prognostic values (high vs low MVD), there was a statistically significant difference in the overall survival among patients with tumors of the oral cavity and larynx (p < 0.001) and in the disease-free survival among patients with tumors of the lower lip (p = 0.01). The prognostic impact of microvessel density was not dependent on clinical stage or lymph node status. The results of the current study suggest that CD105 is a promising target for tumor imaging and prognosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16612622     DOI: 10.1007/s00428-006-0195-4

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  45 in total

1.  NCCN Practice Guidelines for Head and Neck Cancers.

Authors:  D G Pfister; K Ang; B Brockstein; A D Colevas; J Ellenhorn; H Goepfert; W L Hicks; W K Hong; M S Kies; W Lydiatt; T McCaffrey; B B Mittal; J A Ridge; D E Schuller; J P Shah; S Spencer; A Trotti; S Urba; E A Weymuller; R H Wheeler; G T Wolf
Journal:  Oncology (Williston Park)       Date:  2000-11       Impact factor: 2.990

2.  Endoglin (CD105) expression in head and neck basaloid squamous cell carcinoma.

Authors:  Gino Marioni; Elena Gaio; Luciano Giacomelli; Rosario Marchese-Ragona; Claudia Staffieri; Alberto Staffieri; Filippo Marino
Journal:  Acta Otolaryngol       Date:  2005-03       Impact factor: 1.494

3.  Comparison of the diagnostic accuracy of lymphatic endothelium markers: Bayesian approach.

Authors:  Evangelos Evangelou; Panayiotis A Kyzas; Thomas A Trikalinos
Journal:  Mod Pathol       Date:  2005-11       Impact factor: 7.842

4.  The association between tumour progression and vascularity in the oral mucosa.

Authors:  S Pazouki; D M Chisholm; M M Adi; G Carmichael; M Farquharson; G R Ogden; S L Schor; A M Schor
Journal:  J Pathol       Date:  1997-09       Impact factor: 7.996

5.  Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck.

Authors:  W K Hong; S M Lippman; L M Itri; D D Karp; J S Lee; R M Byers; S P Schantz; A M Kramer; R Lotan; L J Peters
Journal:  N Engl J Med       Date:  1990-09-20       Impact factor: 91.245

6.  Prognostic relevance of CD105+ microvessel density in HNSCC patient outcome.

Authors:  Tiziana Martone; Paola Rosso; Roberto Albera; Giuseppe Migliaretti; Flavio Fraire; Lorenzo Pignataro; Giancarlo Pruneri; Graziella Bellone; Giorgio Cortesina
Journal:  Oral Oncol       Date:  2005-02       Impact factor: 5.337

7.  Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer.

Authors:  Reda S Saad; Yulin L Liu; Girija Nathan; James Celebrezze; David Medich; Jan F Silverman
Journal:  Mod Pathol       Date:  2004-02       Impact factor: 7.842

8.  Histopathological analysis of angiogenic factors in renal cell carcinoma.

Authors:  Hiroki Yagasaki; Nozomu Kawata; Yukie Takimoto; Norimichi Nemoto
Journal:  Int J Urol       Date:  2003-04       Impact factor: 3.369

9.  Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer.

Authors:  T C Mineo; V Ambrogi; A Baldi; C Rabitti; P Bollero; B Vincenzi; G Tonini
Journal:  J Clin Pathol       Date:  2004-06       Impact factor: 3.411

10.  Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer.

Authors:  Ester Fonsatti; Michele Maio
Journal:  J Transl Med       Date:  2004-06-11       Impact factor: 5.531

View more
  20 in total

Review 1.  Endoglin-targeted cancer therapy.

Authors:  Ben K Seon; Akinao Haba; Fumihiko Matsuno; Norihiko Takahashi; Masanori Tsujie; Xinwei She; Naoko Harada; Shima Uneda; Tomoko Tsujie; Hirofumi Toi; Hilda Tsai; Yuro Haruta
Journal:  Curr Drug Deliv       Date:  2011-01       Impact factor: 2.565

2.  An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer.

Authors:  Michael S Gordon; Francisco Robert; Daniela Matei; David S Mendelson; Jonathan W Goldman; E Gabriela Chiorean; Robert M Strother; Ben K Seon; William D Figg; Cody J Peer; Delia Alvarez; Bonne J Adams; Charles P Theuer; Lee S Rosen
Journal:  Clin Cancer Res       Date:  2014-09-26       Impact factor: 12.531

3.  Alteration of angiogenic patterns on B16BL6 melanoma development promoted in Matrigel.

Authors:  Shuji Kitahara; Shunichi Morikawa; Kazuhiko Shimizu; Hiroyuki Abe; Taichi Ezaki
Journal:  Med Mol Morphol       Date:  2010-03-26       Impact factor: 2.309

Review 4.  Endoglin for targeted cancer treatment.

Authors:  Lee S Rosen; Michael S Gordon; Francisco Robert; Daniela E Matei
Journal:  Curr Oncol Rep       Date:  2014-02       Impact factor: 5.075

5.  High expression of S100A4 and endoglin is associated with metastatic disease in head and neck squamous cell carcinoma.

Authors:  Marcos Vinícius Macedo de Oliveira; Carlos Alberto de Carvalho Fraga; Lucas Oliveira Barros; Camila Santos Pereira; Sérgio Henrique Sousa Santos; John R Basile; Ricardo Santiago Gomez; André Luiz Sena Guimarães; Alfredo Maurício Batista De-Paula
Journal:  Clin Exp Metastasis       Date:  2014-05-06       Impact factor: 5.150

6.  BCL2 expression in CD105 positive neoangiogenic cells and tumor progression in angioimmunoblastic T-cell lymphoma.

Authors:  Philippe Ratajczak; Christophe Leboeuf; Li Wang; Josette Brière; Irmine Loisel-Ferreira; Catherine Thiéblemont; Wei-Li Zhao; Anne Janin
Journal:  Mod Pathol       Date:  2012-02-10       Impact factor: 7.842

7.  Assessment of angiogenesis by CD105 antigen in epithelial salivary gland neoplasms with diverse metastatic behavior.

Authors:  Sergio V Cardoso; Kelen Christine N Souza; Paulo R Faria; Ana Lucia A Eisenberg; Fernando L Dias; Adriano M Loyola
Journal:  BMC Cancer       Date:  2009-11-04       Impact factor: 4.430

8.  CD105 expression as a measure of microvessel density in supraglottic laryngeal squamous cell carcinoma.

Authors:  Elvir Zvrko; Anton Mikic; Ljiljana Vuckovic
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-04-02       Impact factor: 2.503

9.  Role of platelet derived growth factor receptor (PDGFR) over-expression and angiogenesis in ependymoma.

Authors:  Lucas Moreno; Sergey Popov; Alexa Jury; Saffa Al Sarraj; Chris Jones; Stergios Zacharoulis
Journal:  J Neurooncol       Date:  2012-11-08       Impact factor: 4.130

10.  Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR).

Authors:  Toni K Choueiri; Yousef Zakharia; Sumanta Pal; Judit Kocsis; Russell Pachynski; Alexandr Poprach; Andrew B Nixon; Yingmiao Liu; Mark Starr; Jing Lyu; Kouros Owzar; Mollie deShazo; Primo Lara; Lajos Geczi; Thai H Ho; Meghara Walsh; Bonne Adams; Liz Robertson; Mohamed Darif; Charles Theuer; Neeraj Agarwal
Journal:  Oncologist       Date:  2021-04-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.